Question 13777 — pharmacy and medications

Summary

Ms. Agnès Firmin Le Bodo draws the attention of the Minister of Solidarity and Health to equitable access to innovations. Indeed, the inclusion of an innovative product on the list, and therefore access for patients, is conditional on its level of evaluation by the HAS. He must obtain, in addition to his level of medical service rendered (SMR), a high level of improvement in medical service rendered (ASMR) to be included on this list. If he does not get this level of ASMR, it will not be registered and supported. Thus the ASMR, which was designed in the texts as a tool to help set the price, is diverted from its original objective, since it is used in the context of the list in addition as a criterion for access to reimbursement. Medicines reserved for hospital use and innovative benefiting from a significant SMR are then refused their registration on this list and patients deprived of these innovations. This situation creates a break in equality with the products available in town for which only the SMR is a criterion for access to reimbursement. This worrying situation, which particularly concerns anticancer drugs, is not in line with the Cancer Plan III, one of whose objectives seeks to fight against inequalities and loss of opportunity for patients. Also, she wants to know how it intends to evolve the criteria of the list in addition to re-establish a situation of equitable access to patients for innovative products in the city and in hospitals.

Machine translation from French. The official text remains authoritative.

Timeline

No timeline events have been ingested for this record yet.

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

No documents linked.

Sponsors

No sponsors or actors listed by the source.

Related records

No cross-record relationships stored yet.